@entity1670 -based therapy for XXXX : past evidence and future advances.

@entity1 @entity2299 @entity301 @entity1674 @entity1670 @entity156 @entity5753 @entity412 @entity453 @entity165
Updated guidelines published recently by the National @entity165 Education Program place greater emphasis on @entity2299 , characterized by low high-density lipoprotein (HDL) @entity165 ; elevated @entity1674 ; and small, dense, low-density lipoprotein (LDL) particles, as well as the drugs that can alter the condition. Both low HDL @entity165 and elevated @entity1674 are independent risk factors for @entity453 . Low-density lipoprotein particles can be divided into subclasses with differing atherogenicity. Phenotype A is characterized by large buoyant LDL particles, and phenotype B by small, dense particles associated with increased atherogenicity. The frequency of phenotype B in @entity1 increases as @entity412 levels increase and HDL @entity165 levels decrease. Fibrates and @entity1670 have been shown to improve @entity2299 in clinical trials. @entity1670 effectively lowers @entity1674 , raises HDL @entity165 , and shifts LDL particles to a less atherogenic phenotype (phenotype A). The various @entity1670 formulations available differ in terms of safety and efficacy. When administered alone or in combination with other lipid-modifying agents, @entity1670 prevents progression and promotes regression of @entity301 and reduces coronary risk. Combination therapy is also an effective option for improving @entity156 . In studies, a once-daily, single-tablet combination of @entity1670 extended-release/lovastatin showed additive LDL @entity165 lowering and was more effective than would be anticipated from doubling the component @entity5753 dose. Combination products provide a viable strategy for treating the full spectrum of lipid abnormalities seen in some @entity1 , including those with @entity2299 , and will be increasingly used in the treatment of @entity2299 . Other combination products are currently undergoing clinical testing.
